ADMA Biologics vs Twist Bioscience
ADMA and TWST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADMA and TWST compare
Twist Bioscience is the larger company, worth 3.7 times as much as ADMA Biologics ($9.6B against $2.6B).
Twist Bioscience grew revenue faster over the last twelve months (19.2% versus 8.0% for ADMA Biologics).
ADMA Biologics keeps more of each dollar of sales as profit, with a net margin of 33.0% compared with −31.7% at Twist Bioscience.
ADMA Biologics scores higher on the StockData Score (17 against 13 for Twist Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADMA | TWST |
|---|---|---|
| Size and price | ||
| Market cap | $2.6B | $9.6B |
| Share price | $11.41 | $152.78 |
| Change, 1 year | −26.5% | 374% |
| Change, 5 years | 739% | 12.4% |
| Beta (5Y) | 0.66 | 2.28 |
| Employees | 647 | 979 |
| StockData Score | ||
| Total score | 17 (better) | 13 |
| Valuation score | 5 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 16.3× | – |
| P/S | 5.0× (better) | 22.2× |
| P/B | 6.3× (better) | 21.5× |
| EV/EBITDA | 11.3× | – |
| P/FCF | 21.9× | – |
| FCF yield | 4.6% (better) | −0.97% |
| Fair value | $18.80 | $34.30 |
| Margin of safety | 39.3% (better) | −345% |
| Growth | ||
| Revenue growth (TTM) | 8.0% | 19.2% (better) |
| Revenue growth, 5Y average | 64.6% (better) | 33.1% |
| Net income growth (TTM) | −19.1% | – |
| EPS growth (TTM) | −17.6% | – |
| Profitability | ||
| Gross margin | 64.7% (better) | 52.0% |
| Operating margin | 43.8% (better) | −33.6% |
| Net margin | 33.0% (better) | −31.7% |
| FCF margin | 22.7% (better) | −21.6% |
| Return on equity | 41.9% (better) | −29.6% |
| Return on invested capital | 45.1% (better) | −45.5% |
| Financial health | ||
| Debt / equity | 0.48 (better) | 0.00 |
| Net debt / EBITDA | 0.26 | – |
| Interest coverage | 25.4× | – |
| Current ratio | 6.97 (better) | 2.67 |
| Altman Z-score | 8.02 | 22.67 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | 7.3% | – |
| Shareholder yield | 7.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 91.8% | 122% |
| Held by insiders | 3.0% | 2.3% |
| Insider net buying, 12 months | −$1.1M (better) | −$126M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 9.5% | 17.3% |
Go deeper
- ADMA stock overview
- ADMA income statement
- ADMA valuation and score
- TWST stock overview
- TWST income statement
- TWST valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.